Research programme: Fas receptor antagonists - ONL Therapeutics

Drug Profile

Research programme: Fas receptor antagonists - ONL Therapeutics

Alternative Names: Met12; ONL 1204; ONL101

Latest Information Update: 12 Feb 2016

Price : $50

At a glance

  • Originator ONL Therapeutics
  • Class Peptides; Small molecules
  • Mechanism of Action CD95 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinal detachment
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration; Retinal detachment

Most Recent Events

  • 11 Feb 2016 ONL 1204 receives Orphan Drug status for Retinal detachment in USA
  • 15 Jun 2015 ONL Therapeutics plans a clinical trial for Retinal detachment in USA
  • 19 Nov 2014 ONL Therapeutics receives SBIR grant from National Eye Institute for ONL 101 development in Retinal detachment
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top